Effectiveness and Safety of Zercepac and Reference Trastuzumab in the Neoadjuvant Setting for Early-Stage Breast Cancer: A Retrospective Cohort Study

Table 3

Univariate and multivariate analyses of factors associated with complete pathological response.

Characteristics	Univariate analysis		Multivariate analysis 1		Multivariate analysis 2
	OR (95%CI)		OR (95%CI)		OR (95%CI)
Age	1.02 (0.98-1.07)	0.327
BMI	0.98 (0.88-1.08)	0.646
Menstruation situation
Premenopausal	1
Postmenopausal	0.70 (0.40-1.65)	0.420
Histological grading
Grade 1	1
Grade 2	6.00 (0.84-43.09)	0.075
Grade 3	3.14 (0.49-20.25)	0.228
Time from diagnosis to trastuzumab treatment	1.11 (1.00-1.23)	0.053
ER status
-	1
+	2.00 (0.85-4.66)	0.111
PR status
-	1		1		1
+	3.18 (1.17-8.65)	0.024	4.65 (0.86-25.27)	0.075	5.21 (1.64-16.55)	0.005
Molecular typing
HER2+HR-	1
HER2+HR-	2.09 (0.89-4.91)	0.090
Ki67	1.02 (0.99-1.05)	0.171
Ki67 (ROC cutoff)
≤40%	1
>40%	2.26 (0.95-5.38)	0.065
Maximum tumor diameter	0.93 (0.89-0.97)	<0.001	0.909 (0.85-0.97)	0.005
Maximum tumor diameter (categorical)
≤30 mm	1				1
>30 mm	0.20 (0.08-0.49)	<0.001			0.14 (0.05-0.38)	<0.001
NLR	0.23 (0.13-0.41)	<0.001	0.22 (0.12-0.42)	<0.001
NLR (categorical)
≤2.68	1
>2.68	0.00 (0.00-Inf)	0.989
PLR	1.00 (0.99-1.01)	0.656
PLR (categorical)
≤189.33	1
>189.33	1.82 (0.77-4.32)	0.176
Trastuzumab
Zercepac	1
Reference trastuzumab	0.96 (0.41-2.28)	0.933

Continuous variable was entered as continuous variable. Continuous variable was entered as categorical variables using optimal Youden Index-based cutoff point. OR—odds ratio; BMI—body mass index; HER2—human epidermal growth factor receptor 2; ER—estrogen receptors; PR—progesterone receptors; NLR—neutrophil-to-lymphocyte ratio; PLR—platelet-lymphocyte ratio.